Skip to main content
42 search results for:

Denosumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 05-10-2021 | Rheumatoid arthritis | News | Article

    Denosumab benefits short-lived following discontinuation

    Discontinuing denosumab after 1 year of treatment quickly leads to reversal of its inhibitory effect on bone turnover markers and improvements in bone mineral density among people using glucocorticoids for rheumatoid arthritis, research shows.

  2. 19-08-2020 | Rheumatoid arthritis | News | Article

    Anti-CCP positivity associated with denosumab response in RA patients

    Denosumab may reduce the risk for mTSS worsening among patients with rheumatoid arthritis who have risk factors for radiographic progression, particularly those with anti-cyclic citrullinated peptide antibody positivity, researchers report.

  3. 30-07-2020 | Osteoporosis | Highlight | Teaser
    medwireNews top story

    Delayed denosumab dosing could raise vertebral fracture risk in patients with osteoporosis

    Delaying denosumab injections by more than 16 weeks is associated with an increased risk for vertebral fracture among patients with osteoporosis, study findings indicate.

  4. 30-07-2020 | Osteoporosis | News | Article

    Delayed denosumab dosing could raise vertebral fracture risk in patients with osteoporosis

    Delaying denosumab injections by more than 16 weeks is associated with an increased risk for vertebral fracture among patients with osteoporosis, study findings indicate.

  5. 09-04-2020 | Osteoporosis | News | Article

    Meta-analysis supports efficacy of denosumab for glucocorticoid-induced osteoporosis

    Denosumab significantly increases bone mineral density in people with glucocorticoid-induced osteoporosis and may be more effective than bisphosphonates, show the results of a systematic review and meta-analysis.

  6. 09-09-2019 | Osteoporosis | News | Article

    Denosumab plus high-dose teriparatide may improve postmenopausal osteoporosis

    Combining denosumab with high-dose rather than standard-dose teriparatide results in greater increases in spine and hip bone mineral density in postmenopausal women with osteoporosis, phase IV study data show.

  7. 25-04-2019 | Osteoporosis | News | Article

    No difference in fracture risk with denosumab vs alendronate

    Patients initiating denosumab have a similar 3-year fracture risk to those initiating alendronate, regardless of sex, age, or fracture history, show results of a large study among Danish patients in routine clinical practice.

  8. 17-07-2018 | Osteoporosis | Review | Article

    Denosumab in the treatment of glucocorticoid-induced osteoporosis

    Keywords Denosumab Glucocorticoid-induced osteoporosis Glucocorticoids Osteoporosis 

  9. 24-10-2018 | Osteoporosis | News | Article

    Two-year data support denosumab use in patients with glucocorticoid-induced osteoporosis

    Greater increases in bone mineral density seen with denosumab versus risedronate in glucocorticoid-treated patients with osteoporosis are sustained through 24 months, indicate phase III data.

  10. 27-10-2018 | Osteoporosis | Highlight | Teaser
    medwireNews@ACR/ARHP 2018

    Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

    Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

  11. play
    27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

    Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

    Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

  12. 12-04-2018 | Osteoporosis | News | Article

    Trial results back denosumab as a treatment option for glucocorticoid-induced osteoporosis

    Patients with glucocorticoid-induced osteoporosis who are treated with denosumab have greater improvements in bone mineral density than those treated with risedronate, phase III trial results suggest.

  13. 12-04-2018 | Osteoporosis | Highlight | Teaser
    medwireNews editor's pick

    Trial results back denosumab as a treatment option for glucocorticoid-induced osteoporosis

    Patients with glucocorticoid-induced osteoporosis who are treated with denosumab have greater improvements in bone mineral density than those treated with risedronate, phase III trial results suggest.

  14. 06-09-2018 | Osteoporosis | Article

    Real-world management of women with postmenopausal osteoporosis treated with denosumab: A prospective observational study in the Czech Republic and Slovakia

    Růžičková O et al. Adv Ther 2018. doi: 10.1007/s12325-018-0779-9

  15. 26-07-2017 | Osteoporosis | Article

    Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

    This retrospective analysis found that denosumab significantly improved trabecular bone score independently of bone mineral density in postmenopausal women with osteoporosis. McClung MR, Lippuner K, Brandi ML et al. Osteoporos Int 2017. doi:10.1007/s00198-017-4140-y

  16. 01-07-2017 | Rheumatoid arthritis | Article

    Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: A systematic review of the literature

    The authors review the effect of denosumab on osteoarticular erosive lesions in rheumatoid arthritis and study the potential effects of denosumab on disease activity, joint space narrowing, functional capacity, and safety. Boleto G, Dramé M, Lambrecht I, Eschard JP, Salmon JH. Clin Rheumatol 2017;36:1699–1706. doi:10.1007/s10067-017-3722-6

  17. 21-06-2022 | Glucocorticoids | News | Article

    Low-dose glucocorticoids show no negative impact on BMD

    For higher glucocorticoid doses, there was a negative association with BMD in unadjusted analyses, but this was attenuated after accounting for age, sex, menopause status, BMI, disease duration, alkaline phosphatase levels, and the use of denosumab and bisphosphonates.

  18. 18-02-2019 | Osteoporosis | Editorial | Article

    Osteoporosis therapy: Drug holiday or not?

    Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

  19. 18-02-2019 | Teaser

    Explain the risks of long-term bisphosphonate therapy Identify which patients are suitable for a drug holiday Compare bisphosphonates with denosumab, and explain why denosumab should not be followed by a drug holiday

  20. 18-02-2019 | Osteoporosis | Highlight | Teaser
    Expert opinion editorial

    Osteoporosis therapy: Drug holiday or not?

    Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.